



# A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease

Stefan Grajek<sup>1</sup>, Michał Michalak<sup>2</sup>, Tomasz Urbanowicz<sup>3</sup> and Anna Olasińska-Wiśniewska<sup>3\*</sup>

<sup>1</sup> I Department of Cardiology, Poznan University of Medical Sciences, Poznań, Poland, <sup>2</sup> Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznań, Poland, <sup>3</sup> Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznań, Poland

**Background:** Evidence from recent studies has shown the benefits of colchicine for patients with coronary artery disease. The aim was to assess the effect of colchicine treatment on cardiovascular events, with an estimation of the risk of discontinuation and net clinical benefit.

#### **OPEN ACCESS**

#### Edited by:

Jolanta Siller-Matula, Medical University of Vienna, Austria

#### Reviewed by:

Ceren Eyileten, Medical University of Warsaw, Poland Andrzej Budaj, Medical Centre for Postgraduate Education, Poland

> \*Correspondence: Anna Olasińska-Wiśniewska annaolasinska@ump.edu.pl

#### Specialty section:

This article was submitted to Coronary Artery Disease, a section of the journal Frontiers in Cardiovascular Medicine

> Received: 13 July 2021 Accepted: 31 October 2021 Published: 09 December 2021

#### Citation:

Grajek S, Michalak M, Urbanowicz T and Olasińska-Wiśniewska A (2021) A Meta-Analysis Evaluating the Colchicine Therapy in Patients With Coronary Artery Disease. Front. Cardiovasc. Med. 8:740896. doi: 10.3389/fcvm.2021.740896 **Methods and Results:** Fourteen trials with a total of 13,186 patients were selected through a systematic search. Colchicine therapy significantly reduced the relative risk of primary endpoint by about 30% [RR 0.70 (95%CI:0.56–0.88)]. Compared with placebo, colchicine significantly reduced the risk of ischemia-driven revascularization [RR 0.57 (95%CI 0.41–0.80)], ischemia-driven revascularization and resuscitation [RR 0.50 (95%CI 0.34–0.73)], myocardial infarction [RR 0.73 (95%CI 0.57–0.95)], and stroke [RR 0.49 (95%CI 0.30–0.7)]. Patients treated with colchicine in comparison with placebo have a significant increase in the risk of treatment cessation (RR 1.60 95%CI 1.06–2.42). However, in the analysis which excluded studies without placebo, the relative risk of discontinuation was lower and insignificant [RR 1.26 (95%CI 0.87–1.83)]. The net clinical benefit was 17.8/1,000 patients (p < 0.001).

**Conclusion:** In coronary artery disease, low-dose colchicine significantly reduces the risk of the primary composite endpoint by about 30%. The drug should be considered as part of the preventive treatment in patients with good tolerance.

Keywords: colchicine, coronary artery disease, discontinuation, net clinical benefit, inflammation, cardiac outcomes

# INTRODUCTION

Colchicine is an established treatment for gout, Behcet's Disease, and Familial Mediterranean Fever (1). Recent literature suggests that colchicine has cardiovascular benefits in patients with coronary artery disease (CAD), with a decrease in the risk of myocardial infarction and other cardiac outcomes by reducing inflammation (2–4). Colchicine at a dose of 0.5 mg

once daily reduces inflammasome (NLRP3) activation and neutrophil degranulation (5, 6). Additionally, in patients with CAD with high leukocyte activation (> 7,500 WBC/mm<sup>2</sup>), endothelial function is significantly improved (7). Vaidva et al. (8) suggested that low-dose colchicine therapy in the postacute coronary syndrome (ACS) of patients favorably modifies coronary plaque, independent of high-dose statin intensification therapy and substantial low-density lipoprotein reduction. The same group of researchers proved that colchicine inhibits neutrophil extracellular trap formation in ACS post percutaneous coronary intervention (PCI) (9). In addition, colchicine is a relatively safe and low-cost medication, which has been available for many years. Since 2019, three large clinical randomized studies have been published that proved a favorable effect of colchicine on cardiovascular events in patients with CAD (10-12). However, some meta-analyses did not confirm these results (13-15). These inconclusive observations were the source of the present systematic review and meta-analysis. The aim was to assess the effect of colchicine treatment on cardiovascular events. Additionally, to the best of our knowledge, this is the first estimation of the risk of discontinuation of colchicine therapy and net clinical benefit.

# METHODS

The study conducted following the preferred was (PRISMA) reporting items for meta-analysis recommendations and was registered with the International Prospective Register Systematic of Reviews (PROSPERO).

## **Search Strategy and Selection Criteria**

We conducted a systematic search of studies in PubMed, Embase, The Cochrane Library, and Web of Science until February 11, 2021. The keywords used in the search process were as follows: ("colchicine") AND ("coronary artery disease" OR "CAD" OR "coronary heart disease" OR "CHD" OR "acute coronary syndrome" OR "ACS" OR "myocardial infarction" OR "MI" OR "angina" OR "ischemic heart disease" OR "percutaneous coronary intervention" OR "PCI").

The analysis included patients with CAD and ACS. Studies that fulfilled the following inclusion criteria were selected for the meta-analysis: 1. randomized controlled trial (RCT), comparing the effect of colchicine vs. placebo



#### TABLE 1 | Study outcomes.

|                | Primary endpoint | Cardiovascular<br>mortality | Ischemia<br>driven<br>revascularization | Ischemia driven<br>revascularization +<br>resuscitation | Myocardial infarction | Stroke | Death | Hs CRP |
|----------------|------------------|-----------------------------|---|---|-----------------------|--------|-------|--------|
| Nidorf (11)    | +                | +                           | +                                       |   | +                     | +      | +     |        |
| Shah (16)      | +                |                             |   |   | +                     |        | +     | +      |
| Tong (12)      | +                | +                           | +                                       |   | +                     | +      | +     |        |
| Tardif (10)    | +                | +                           | +                                       | +   | +                     | +      | +     |        |
| Nidorf (17)    | +                | +                           | +                                       | +   | +                     | +      | +     |        |
| Deftereos (18) |                  | +                           |   |   |                       |        | +     |        |
| Deftereos (19) |                  | +                           | +                                       |   |                       | +      | +     |        |
| Hennessy (20)  |                  |                             | +                                       |   | +                     |        |       | +      |
| Akodad (21)    |                  |                             |   |   | +                     |        |       |        |
| Raju (22)      |                  |                             |   |   |                       | +      |       | +      |
| O'Keefe (23)   |                  |                             |   |   |                       |        | +     |        |
| Kajikawa (7)   |                  |                             |   |   |                       |        |       | +      |
| Vaidya (8)     |                  |                             |   |   |                       |        |       | +      |
| Nidorf (24)    |                  |                             |   |   |                       |        |       | +      |

Hs CRP, high sensitive C-reactive protein.

CAD or ACS patients, 2. reported study outcomes consistent with those focused in the present meta-analysis, 3. minimum follow-up period of 6 months. Registries, published abstracts, and meeting presentations were excluded. Finally, 14 studies were included in the analysis (**Figure 1**).

#### **Study Outcomes**

Study outcomes were primary endpoints as defined in the particular study, other cardiac outcomes, and high-sensitive C-reactive protein (hs-CRP) (**Table 1**).

#### **Data Synthesis and Analysis**

The methodological quality of randomized studies was assessed using the Cochrane Collaboration tool for assessing the risk of bias. For each clinical trial, bias was assessed qualitatively as low, unclear, or high (Supplementary Table 1). The assessment was made independently by two authors (SG and MM). To compare the results of colchicine vs. placebo patients, a meta-analysis using a random model was performed. As a measure of the effect, the Mantel-Haenszel relative risk (RR) with 95% confidence interval was used and in the case of hs-CRP analysis, the effect was measured as standardized mean difference (SMD). The data in the analyzed studies reported hs-CRP either as mean and SD or median and interquartile ranges (IQR). To enable the analysis for all those studies, we assumed the normal distribution of data and used the relationship between analyzed descriptive statistics: mean = median and SD = IQR/1.35. As a measure of heterogeneity, I2 statistics based on the Q-Cochran test were used. We calculated the net clinical benefit as the difference between the primary endpoint reduction and the increase of discontinuation ratio in colchicine vs. placebo patients. The result is expressed as a number of events per 1,000 patients.

Additionally, we performed a sensitivity analysis taking into account studies with a sample size greater than 100 in both arms and the follow-up was longer than 6 months. The calculations were performed using Review Manager (RevMan 5.3 Cochrane Community. Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014). A prospective protocol was uploaded to the PROSPERO online platform, with the registration number CRD42020218138.

## RESULTS

A total of 226 studies were examined for eligibility, of which 14 papers were finally selected. A total of 13,186 patients who met the inclusion criteria (**Figure 1**) were included in the final analysis. A total number of 11,790 patients were included in the sensitivity analysis (**Supplementary Material**). Baseline patient characteristic for each study is summarized in **Table 2**. The mean age of the patients ranged from 56.3 to 68.7 years, with men accounting for 82.7% of the population. Ten trials used placebo and four were openlabel type.

## **Efficacy Endpoints**

The primary endpoint defined as cardiovascular death or myocardial infarction or ischemic stroke or ischemia

#### TABLE 2 | Baseline patient characteristics.

| References                         | Type of<br>comparator                           | N            | Age   | Male                        | Diagnosis   | Previous<br>Stroke   | DM                       | HA                          | HL                       | Previous<br>MI/ACS             | Previous<br>PCI                | Previous<br>CABG        | HF                   | Tobacco<br>smoking                         |
|------------------------------------|---|--------------|---|-----------------------------|---|----------------------|--------------------------|-----------------------------|--------------------------|--------------------------------|--------------------------------|-------------------------|----------------------|--|
| O'Keefe (23)                       | Colchicine<br>Placebo                           | 130<br>67    | 59 62   | 111 (85)<br>58 (87)         | SCAD  | -                    | 16 (12)<br>8 (12)        | -                           | -                        | -                              | -                              | 34 (26)<br>17 (25)      | -                    | -  |
| Nidorf (24)                        | Colchicine Control                              | 44<br>20     | $\begin{array}{c} 62\pm10\\ 59\pm10\end{array}$             | 36 (81)<br>17 (85)          | SCAD  | -                    | -                        | -                           | -                        | -                              | -                              | -                       | -                    | -  |
| Raju et al. (22)                   | Colchicine<br>Placebo                           | 40<br>40     | 57.2 (11.7)<br>57.2 (8.7)                                   | 34 (85)<br>37 (92.5)        | UA 8 (20)<br>UA 3 (7.5)<br>MI 27 (67.5)<br>MI 35 (87.5)                         | 3 (7.5)<br>0 (0)     | 7 (17.5)<br>6 (15)       | 19 (47.5)<br>15 (37.5)      | 19 (47.5)<br>19 (47.5)   | 8 (20)<br>6 (15)               | -                              | -                       | 1(2.5)<br>0 (0)      | 18 (45)<br>17 (42.5)                       |
| Nidorf et al. (17)<br>LODoCO       | Colchicine Control                              | 282<br>250   | $\begin{array}{c} 66\pm9.6\\ 67\pm9.2\end{array}$           | 251 (89)<br>222 (89)        | -   | -                    | 92 (33)<br>69 (28)       | -                           | -                        | MI or UA<br>64 (23)<br>61 (24) | 169 (60)<br>138 (55)           | 62 (22)<br>39 (16)      | -                    | 10 (4)<br>14 (6)                           |
| Deftereos et al. (19)              | Colchicine<br>Placebo                           | 100<br>96    | $\begin{array}{c} 63.7 \pm 6.9 \\ 63.5 \pm 7.2 \end{array}$ | 63 (63)<br>65 (68)          | SCAD 72 (72)<br>SCAD<br>63 (66) ACS<br>28 (28) ACS<br>33 (34)                   | -                    | 100 (100)<br>96 (100)    | 48 (48)<br>47 (49)          | -                        | -                              | -                              | -                       | -                    | 36 (36)<br>38 (40)                         |
| Deftereos et al. (18)              | Colchicine<br>Placebo                           | 140<br>139   | $66.9 \pm 5.8$<br>$66.4 \pm 5.7$                            | 94 (67)<br>93 (67)          | Stable HF   | -                    | 23 (16)<br>25 (18)       | 48 (34)<br>53 (38)          | 46 (33)<br>45 (32)       | -                              | -                              | -                       | all                  | -  |
| Vaidya (8)                         | Colchicine Control                              | 40<br>40     | $56.3 \pm 8.9$<br>$58.4 \pm 14.2$                           | 32 (80)<br>30 (75)          | STEMI 3 (7.5)<br>6 (15) NSTEMI<br>14 (35)<br>16 (40)<br>UA 23 (57.5)<br>16 (40) | -                    | 9 (22.5)<br>16 (40)      | 20 (50)<br>23 (57.5)        | 34 (85)<br>34 (85)       | 19 (47.5)<br>22 (55)           | 28 (70)<br>23 (57.5)           | -                       | -                    | 20 (50)<br>21 (52.5)                       |
| Akodad et al.<br>(21) COLIN        | Colchicine Control                              | 23<br>21     | 60.1 ± 13.1<br>59.7 ± 11.4                                  | 19 (82.5)<br>16 (76.2)      | STEMI   | -                    | 3 (13.0)<br>3 (14.3)     | 9 (39.1)<br>10 (47.6)       | 8 (34.8)<br>8 (38.1)     | -                              | 1 (4.3)<br>1 (4.8)             | 0 (0)<br>1 (4.8)        | 9 (39.1)<br>5 (23.8) | 17 (73.9)<br>14 (66.7)                     |
| Tardif et al. (10)<br>COLCOT       | Colchicine<br>Placebo                           | 2366<br>2379 | $60.6 \pm 10.7$<br>$60.5 \pm 10.6$                          | 1894 (80)<br>1942<br>(81.6) | CAD within 30<br>days after MI  | 55 (2.3)<br>67 (2.8) | 462 (19.5)<br>497 (20.9) | 1185<br>(50.1)<br>1236 (52) | -                        | 370 (15.6)<br>397 (16.7)       | 392 (16.6)<br>406 (17.1)       | 69 (2.9)<br>81 (3.4)    | 48 (2)<br>42 (1.8)   | 708 (29.9)<br>708 (29.8)                   |
| Hennessy et al. (20)               | Colchicine<br>Placebo                           | 119<br>118   | $61 \pm 13.6$<br>$61 \pm 12.5$                              | 89 (75)<br>93 (79)          | Acute<br>Ml, including<br>STEMI 63 (53)<br>71 (60)                              | -                    | 27 (23)<br>25 (21)       | 64 (54)<br>48 (41)          | -                        | 18 (15)<br>18 (15)             | Prior revasc<br>13 (1<br>14 (1 | ularisation<br>1)<br>2) | -                    |  |
| Kajikawa (7)                       | Colchicine<br>Placebo (data for<br>whole group) | 28           | 68 ± 7  | 27 (96.4)                   |   | 1 (3.6)              | 10 (35.7)                | 25 (89.3)                   | -                        | 16 (57.1)                      | 20 (71.4)                      | 1 (3.6)                 |                      | Current 8<br>(28.6)<br>Former 27<br>(96.4) |
| Shah et al. (16)<br>COLCHICINE-PCI | Colchicine<br>Placebo                           | 206<br>194   | 65.9 + 9.9<br>$66.6 \pm 10.2$                               | 193 (93.7)<br>181 (93.3)    | ACS 103 (50.0)<br>ACS 95 (49.0)   | -                    | 114 (55.3)<br>117 (60.3) | 192 (93.2)<br>175 (90.2)    | 182 (88.3)<br>173 (89.2) | 51 (24.8)<br>52 (26.8)         | -                              | -                       | -                    | 43 (20.9)<br>46 (23.7)                     |

Grajek et al.

(Continued)

| References         | Type of<br>comparator | Z    | Age Male                            | Diagnosis                          | Previous<br>Stroke | DM         | ЧΑ                       | Ŧ        | Previous<br>MI/ACS       | Previous<br>PCI          | Previous<br>CABG | Η | Tobacco<br>smoking |
|--------------------|-----------------------|------|-------------------------------------|------------------------------------|--------------------|------------|--------------------------|----------|--------------------------|--------------------------|------------------|---|--------------------|
| Nidorf et al. (11) | Colchicine            | 2762 | 65.8 ± 8.4 2305                     | CAD                                |                    | 492 (17.8) | 1421                     |          | 2323                     | 2100                     | 319 (11.5)       |   | 318 (11.5)         |
| LoDoCo 2           | Placebo               | 2760 | 65.9 ± 8.7 (83.5)<br>2371<br>(85.9) |                                    |                    | 515 (18.7) | (51.4)<br>1387<br>(50.3) |          | (84.1)<br>2335<br>(84.6) | (76.0)<br>2077<br>(75.3) | 391 (14.2)       |   | 330 (12.0)         |
| Tong et al. (12)   | Colchicine            | 396  | 59.7 ± 10.2 322 (5                  | <ol> <li>STEMI 182 (48)</li> </ol> | 5 (1)              | 75 (19)    | 201 (51)                 | 180 (46) | 59 (15)                  | 51 (13)                  | 15 (4)           |   | 128 (32)           |
| COPS               | Placebo               | 399  | 60.0 ± 10.4 310 (7                  | 78) STEMI208 (53)                  | 11 (3)             | 76 (19)    | 199 (50)                 | 185 (46) | 59 (15)                  | 50 (13)                  | 19 (5)           |   | 149 (37)           |
|                    |                       |      |                                     | NSTEMI                             |                    |            |                          |          |                          |                          |                  |   |                    |
|                    |                       |      |                                     | 183 (48)                           |                    |            |                          |          |                          |                          |                  |   |                    |
|                    |                       |      |                                     | NSTEMI                             |                    |            |                          |          |                          |                          |                  |   |                    |
|                    |                       |      |                                     | 174 (44)                           |                    |            |                          |          |                          |                          |                  |   |                    |
|                    |                       |      |                                     | UA 15 (4)                          |                    |            |                          |          |                          |                          |                  |   |                    |
|                    |                       |      |                                     | UA 11 (3)                          |                    |            |                          |          |                          |                          |                  |   |                    |

elevation myocardial infarction; PCI, percutaneous intervention; SCAD, stable coronary artery disease; STEMI, ST elevation myocardial infarction, UA, unstable angina

driven revascularization or PCI-related myocardial injury was calculated in five studies (Table 1). Colchicine therapy significantly reduced the relative risk coefficient of the primary endpoint by about 30% [RR 0.70 (95% CI:0.56-0.88), Figure 2A]. In the sensitivity analysis which included four studies (Supplementary Figure 2A), the risk of the primary endpoint was similar [RR 0.64 (95% CI 0.50-0.82)]. Compared with placebo, colchicine significantly reduced the risk of ischemia driven revascularization [RR 0.57 (95% CI 0.41-0.80), Figure 2C], ischemia driven revascularization and resuscitation [RR 0.50 (95% CI 0.34-0.73), Figure 2D], myocardial infarction [RR 0.73 (95% CI 0.57-0.95), Figure 3A], and stroke [RR 0.49 (95% CI 0.30-0.7), Figure 3B]. In the sensitivity analysis, the results were consistent and always significant (Supplementary Figures 2, 3). Colchicine did not significantly reduce the risk of cardiovascular death and overall death (Figures 2B, 3C). Colchicine therapy was associated with a significant reduction in hs-CRP level (Figure 3D). Figure 4 presents the Number Need to Treat (NNT) for the significantly reduced primary endpoint and other cardiovascular events.

#### Safety Endpoints

The overall relative risk (RR) of discontinuation with colchicine therapy is presented in **Figure 5A**. Patients treated with colchicine in comparison with placebo have a significant increase in the risk of treatment cessation (RR 1.60 95% CI 1.06–2.42), but the analysis of excluded studies without placebo (PROBE studies) had a lesser relative risk of discontinuation (RR 1.34 95% CI 0.97–1.84) (**Figure 5B**). After the inclusion of only the three largest studies, the RR of discontinuation was the lowest and insignificant [RR 1.26 (95% CI 0.87– 1.83), **Figure 5C**]. The net clinical benefit calculated as the difference between primary endpoint reduction and discontinuation ratio in colchicine vs. placebo patients was 17.8/1,000 patients (p < 0.001) and is presented in **Figure 5D**.

### DISCUSSION

The results of our meta-analysis prove that treatment with colchicine at a dose 0.5 mg once daily in patients with CAD significantly reduces the primary endpoint composed of cardiovascular mortality, myocardial infarction, stroke, and urgent ischemia-driven revascularization by 30% (relative risk). The estimated NNT is 36 (26-58) on average. This result does not confirm the negative results of other metaanalyses, which have shown a favorable reduction of ischemic events, although the differences were not significant (13-15). Additionally, we proved that colchicine treatment significantly reduces the relative risk of myocardial infarction (27%), ischemia-driven revascularization (43%), and stroke (51%). Our results are consistent with the two most recent metaanalyses (25, 26). The reasons for this discrepancy should be seen in the number of patients included in the assessment. Among all cited meta-analyses, ours contains the largest number of 13,186 (7, 8, 10-12, 16-24). After excluding

| •   | 01   | Colchie   | cine                                       | Placel                              | 00                                   | MI-1-1-2                                  | Risk Ratio                                    | Risk Ratio   |
|-----|--|---|--|-------------------------------------|--------------------------------------|---|---|--|
|     | Study or Subgroup  | Events  | Iotal                                      | Events                              | Iotal                                | Weight                                    | M-H, Random, 95% CI                           | M-H, Random, 95% CI  |
|     | Nidorf 2020  | 187   | 2762                                       | 264                                 | 2760                                 | 25.8%                                     | 0.71 [0.59, 0.85]                             |  |
|     | Shah 2020  | 118   | 206  | 122                                 | 194                                  | 26.7%                                     | 0.91 [0.78, 1.07]                             |  |
|     | Tong 2020  | 121   | 390  | 41                                  | 399                                  | 13.0%                                     | 0.59 [0.36, 0.96]                             |  |
|     | Nidorf 2013  | 15  | 2300                                       | 40                                  | 250                                  | 23.9%<br>10.6%                            | 0.33 [0.19, 0.59]                             | ¯  |
|     | Total (95% CI)   |   | 6012                                       |                                     | 5982                                 | 100.0%                                    | 0 70 [0 55 0 88]                              |  |
|     | Total (00 / 01)  | 475   | 0012                                       | 627                                 | JJUL                                 | 100.070                                   | 0.10 [0.00, 0.00]                             | •  |
|     | Hotorogonoity: Tau <sup>2</sup> =  | 475<br>- 0.04 · Chi2  | - 15 69                                    | 037<br>8 df = 4 (                   | <b>D</b> – 0 0                       | 03).  2 - 7                               | 10/_  |  |
|     | Test for overall effect:   | Z = 3.08 (I   | P = 0.00                                   | )2)                                 | 0.0                                  | 03), + - 7                                | + /0  | 0.1 0.2 0.5 1 2 5 10<br>Favours [Colchicine] Favours [Placebo] |
|     |  | Colchic   | ine  | Place                               | 00                                   |   | Risk Ratio                                    | Risk Ratio   |
|     | Study or Subgroup  | Events  | Total                                      | Events                              | Total                                | Weight                                    | M-H, Random, 95% Cl                           | M-H, Random, 95% Cl  |
|     | Nidorf 2020  | 20  | 2762                                       | 25                                  | 2760                                 | 42.9%                                     | 0.80 [0.45, 1.44]                             |  |
|     | Tong 2020  | 3   | 396  | 1                                   | 399                                  | 2.9%                                      | 3.02 [0.32, 28.94]                            |  |
|     | Tardif 2019  | 20  | 2366                                       | 24                                  | 2379                                 | 42.2%                                     | 0.84 [0.46, 1.51]                             | — <b>—</b> — <b>—</b> —  |
|     | Deftereos 2014   | 4   | 140  | 5                                   | 139                                  | 8.8%                                      | 0.79 [0.22, 2.90]                             |  |
|     | Deftereos 2013   | 0   | 100  | 1                                   | 96                                   | 1.4%                                      | 0.32 [0.01, 7.76]                             | ← → ↓  |
|     | Nidorf 2013  | 0   | 282  | 5                                   | 250                                  | 1.8%                                      | 0.08 [0.00, 1.45]                             | <  |
|     | Total (95% CI)   |   | 6046                                       |                                     | 6023                                 | 100.0%                                    | 0.80 [0.55, 1.18]                             | ◆  |
|     | Total events   | 47  |  | 61                                  |                                      |   |   |  |
|     | Heterogeneity: Tau <sup>2</sup> =<br>Test for overall effect:  | 0.00; Chi <sup>2</sup><br>Z = 1.12 (F                               | = 4.14,<br>P = 0.26                        | df = 5 (P<br>)                      | = 0.53                               | );  ² = 0%                                |   | 0.1 0.2 0.5 1 2 5 10<br>Favours [Colchicine] Favours [Placebo] |
|     |  | Colchic   | ine  | Placel                              | 00                                   |   | Risk Ratio                                    | Risk Ratio   |
|     | Study or Subgroup  | Events  | Total                                      | Events                              | Total                                | Weight                                    | M-H, Random, 95% C                            | M-H, Random, 95% Cl  |
|     | Nidorf 2020  | 135   | 2762                                       | 177                                 | 2760                                 | 45.4%                                     | 0.76 [0.61, 0.95]                             |  |
|     | Tong 2020  | 3   | 396  | 12                                  | 399                                  | 6.4%                                      | 0.25 [0.07, 0.89]                             | · • • • • • • • • • • • • • • • • • • •                        |
|     | Tardif 2019  | 25  | 2366                                       | 50                                  | 2379                                 | 26.5%                                     | 0.50 [0.31, 0.81]                             |  |
|     | Hennessy 2019  | 0   | 111  | 2                                   | 113                                  | 1.2%                                      | 0.20 [0.01, 4.19]                             | •  |
|     | Deftereos 2013   | 4   | 100  | 5                                   | 96                                   | 6.2%                                      | 0.77 [0.21, 2.77]                             | · · · · · · · · · · · · · · · · · · ·                          |
|     | Nidorf 2013  | 9   | 282  | 20                                  | 250                                  | 14.4%                                     | 0.40 [0.19, 0.86]                             |  |
|     | Total (95% CI)   |   | 6017                                       |                                     | 5997                                 | 100.0%                                    | 0.57 [0.41, 0.80]                             | ▲  |
|     | Total events   | 176   |  | 266                                 |                                      |   |   |  |
|     | Heterogeneity: Tau <sup>2</sup> =  | 0.05; Chi <sup>2</sup>  | = 7.48,                                    | df = 5 (P                           | ,<br>D                               |   |   |  |
| - 1 | Test for overall effect:   | Test for overall effect: Z = 3.25 (P = 0.001)                       |  |                                     |                                      |   |   | Favours [Colchicine] Favours [Placebo]                         |
|     |  | Colchie   | ine  | Place                               | 00                                   | 100000 (r. 1000 m.                        | Risk Ratio                                    | Risk Ratio   |
| )   |  |   | Total                                      | Events                              | Total                                | Weight                                    | M-H, Random, 95% CI                           | M-H, Random, 95% Cl  |
| )   | Study or Subgroup  | Events  | Total                                      |                                     |                                      | 73 30/                                    | 0.54 [0.35, 0.84]                             |  |
|     | Study or Subgroup  | Events<br>30  | 2366                                       | 56                                  | 2379                                 | 10.070                                    |   |  |
|     | Study or Subgroup<br>Tardif 2019<br>Nidorf 2013  | Events<br>30<br>10  | 2366<br>282                                | 56<br>22                            | 2379<br>250                          | 26.7%                                     | 0.40 [0.19, 0.83]                             | <b>_</b> _   |
|     | <u>Study or Subgroup</u><br>Tardif 2019<br>Nidorf 2013<br>Total (95% CI)   | Events<br>30<br>10  | 2366<br>282<br>2648                        | 56<br>22                            | 2379<br>250<br>2629                  | 26.7%                                     | 0.40 [0.19, 0.83]<br>0.50 [0.34, 0.73]        | <br>◆  |
| 1   | Study or Subgroup<br>Tardif 2019<br>Nidorf 2013<br>Total (95% CI)<br>Total events  | Events<br>30<br>10<br>40  | 2366<br>282<br>2648                        | 56<br>22<br>78                      | 2379<br>250<br>2629                  | 26.7%                                     | 0.40 [0.19, 0.83]<br><b>0.50 [0.34, 0.73]</b> | •  |
| )   | Study or Subgroup<br>Tardif 2019<br>Nidorf 2013<br>Total (95% CI)<br>Total events<br>Heterogeneity: Tau <sup>2</sup> =<br>Test for overall effect: | Events<br>30<br>10<br>40<br>• 0.00; Chi <sup>2</sup><br>Z = 3.63 (F | 2366<br>282<br>2648<br>= 0.45,<br>P = 0.00 | 56<br>22<br>78<br>df = 1 (P<br>003) | 2379<br>250<br><b>2629</b><br>= 0.50 | 26.7%<br>100.0%<br>); l <sup>2</sup> = 0% | 0.40 [0.19, 0.83]<br>0.50 [0.34, 0.73]        | 0.1 0.2 0.5 1 2 5 10<br>Eavours [Colchicipe] Eavours [Placebol |

small observational clinical trials, 11,790 patients were included in the sensitivity meta-analysis and the results were almost identical to those in the main meta-analysis (**Supplementary Material**). This confirms the reliability and robustness of the obtained results. Like all other investigators, we did not find a significant effect of the drug on cardiovascular and total mortality. In the cited studies, the beneficial effect of colchicine treatment was observed in both chronic (CCS) and acute (ACS) coronary syndromes. In the latter, the therapeutic efficacy of colchicine was greater

|   |   | Colch   | icine  | Place   | bo   |   | Risk Ratio  | Risk Ratio   |
|---|---|---|--|---|--|---|---|--|
|   | Study or Subgroup   | Events  | Total  | Events  | Total  | Weight  | M-H, Random, 95% CI   | M-H, Random, 95% Cl  |
|   | Nidorf 2020   | 83  | 2762   | 116   | 2760   | 43.5%   | 0.71 [0.54, 0.94]   |  |
|   | Shah 2020   | 0   | 206  | 1   | 194  | 0.6%  | 0.31 [0.01, 7.66]   | · · · ·  |
|   | Tong 2020   | 7   | 396  | 11  | 399  | 6.8%  | 0.64 [0.25, 1.64]   |  |
|   | Hennessy 2019   | 0   | 111  | 2   | 113  | 0.7%  | 0.20 [0.01, 4.19]   | ← .  |
|   | Tardif 2019   | 89  | 2366   | 98  | 2379   | 42.7%   | 0.91 [0.69, 1.21]   |  |
|   | Akodad 2017   | 0   | 23   | 1   | 21   | 0.6%  | 0.31 [0.01, 7.12]   | ← · · · · · · · · · · · · · · · · · · ·  |
|   | Nidorf 2013   | 4   | 282  | 14  | 250  | 5.1%  | 0.25 [0.08, 0.76]   | ·  |
|   | Total (95% CI)  |   | 6146   |   | 6116   | 100.0%  | 0.73 [0.57, 0.95]   | •  |
|   | Total events  | 183   |  | 243   |  |   |   |  |
|   | Heterogeneity: Tau <sup>2</sup>   | = 0.02; Chi   | <sup>2</sup> = 7.16,   | df = 6 (F   | P = 0.3  | 1); l² = 16%  |   |  |
|   | Test for overall effec  | t: Z = 2.39   | (P = 0.02)   | 2)  |  |   | I   | Favours [Colchicine] Favours [Placebo]   |
| 1 | _   | Colchi  | cine   | Place   | bo   |   | Risk Ratio  | Risk Ratio   |
|   | Study or Subgroup   | Events  | Total  | Events  | Total  | Weight  | M-H, Random, 95% CI   | M-H, Random, 95% CI  |
|   | Nidorf 2020   | 16  | 2762   | 24  | 2760   | 57.8%   | 0.67 [0.35, 1.25]   | , /  |
|   | Tong 2020   | 2   | 396  | <del>1</del> _  | 300  | 9.0%  | 0.34 [0.07 1.65]  | ← <u> </u>   |
|   | Tardif 2010   | 2   | 2266   | 10  | 2270   | 23 00/0   | 0.04 [0.07, 1.00]   |  |
|   | Dofference 2012   | 0   | 100  | 19  | 2019   | 20.0%   | 2 99 [0 12 60 97]   |  |
|   | Nidorf 2012   | 1   | 001  | 0   | 30   | 2.3%  |   | ←  |
|   | Reiu 2013   | 1   | 202  | 4   | 200  | 4.0%  | 0.22 [0.02, 1.97]   |  |
|   | Raju 2012   | 0   | 30   | 1   | 38   | 2.3%  | 0.55 [0.01, 8.36]   |  |
|   | Total (95% CI)  |   | 5942   |   | 5922   | 100.0%  | 0.49 [0.30, 0.78]   | ◆  |
|   | Total events  | 25  |  | 54  |  |   |   |  |
|   | Heterogeneity: Tau <sup>2</sup>   | = 0.00; Chi   | ² = 4.39,  | df = 5 (F   | P = 0.50   | 0); I² = 0%   |   |  |
|   | Test for overall effect   | t: Z = 2.95   | P = 0.00   | 13)   |  |   |   | Favours [Colchicine] Favours [Placebo]   |
|   |   | Colchi  | cine   | Place   | bo   |   | Risk Ratio  | Risk Ratio   |
|   | Study or Subgroup   | Events  | Total  | Events  | Total  | Weight  | M-H, Random, 95% Cl   | M-H, Random, 95% Cl  |
|   | Nidorf 2020   | 73  | 2762   | 60  | 2760   | 39.6%   | 1.22 [0.87, 1.70]   |  |
|   | Shah 2020   | 1   | 206  | 1   | 194  | 1.8%  | 0.94 [0.06, 14.95]  | • •  |
|   | Tong 2020   | 8   | 396  | 1   | 399  | 3.2%  | 8.06 [1.01, 64.15]  |  |
|   | -   |   | 0000   |   | 2270   | 04 40/  |   |  |
|   | Tardif 2019   | 43  | 2366   | 44  | 2010   | 34.1%   | 0.98 [0.65, 1.49]   |  |
|   | Tardif 2019<br>Deftereos 2014   | 43<br>4   | 2366<br>140  | 44<br>5   | 139  | 34.1%<br>7.6%   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]  |  |
|   | Tardit 2019<br>Deftereos 2014<br>Deftereos 2013   | 43<br>4<br>1  | 2366<br>140<br>100   | 44<br>5<br>1  | 139<br>96  | 34.1%<br>7.6%<br>1.9%   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]  | ← <u> </u>   |
|   | Tardit 2019<br>Deftereos 2014<br>Deftereos 2013<br>Nidorf 2013  | 43<br>4<br>1<br>4   | 2366<br>140<br>100<br>282  | 44<br>5<br>1  | 139<br>96<br>250   | 34.1%<br>7.6%<br>1.9%<br>9.3%   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]   |  |
|   | Tardif 2019<br>Deftereos 2014<br>Deftereos 2013<br>Nidorf 2013<br>O'Keefe 1992  | 43<br>4<br>1<br>4<br>1  | 2366<br>140<br>100<br>282<br>130   | 44<br>5<br>1<br>10<br>2   | 139<br>96<br>250<br>67   | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]  |  |
|   | Deftereos 2014<br>Deftereos 2014<br>Deftereos 2013<br>Nidorf 2013<br>O'Keefe 1992   | 43<br>4<br>1<br>4<br>1  | 2366<br>140<br>100<br>282<br>130   | 44<br>5<br>10<br>2  | 139<br>96<br>250<br>67   | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]  |  |
|   | Tardif 2019<br>Deftereos 2014<br>Deftereos 2013<br>Nidorf 2013<br>O'Keefe 1992<br>Total (95% CI)  | 43<br>4<br>1<br>4<br>1  | 2366<br>140<br>100<br>282<br>130<br><b>6382</b>  | 44<br>5<br>1<br>10<br>2   | 139<br>96<br>250<br>67<br>6284   | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%<br>100.0%   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]   |  |
|   | Tardif 2019<br>Deftereos 2014<br>Deftereos 2013<br>Nidorf 2013<br>O'Keefe 1992<br>Total (95% CI)<br>Total events  | 43<br>4<br>1<br>4<br>1<br>135   | 2366<br>140<br>100<br>282<br>130<br>6382   | 44<br>5<br>1<br>10<br>2<br>124  | 139<br>96<br>250<br>67<br>6284   | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%<br>100.0%   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]   |  |
|   | Tardif 2019<br>Deftereos 2014<br>Deftereos 2013<br>Nidorf 2013<br>O'Keefe 1992<br>Total (95% CI)<br>Total events<br>Heterogeneity: Tau <sup>2</sup>   | 43<br>4<br>1<br>4<br>1<br>355<br>= 0.07; Chir   | 2366<br>140<br>100<br>282<br>130<br>6382<br>* = 9.51,  | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P   | 139<br>96<br>250<br>67<br>6284   | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%<br><b>100.0%</b><br>2); I <sup>2</sup> = 26%  | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]   |  |
|   | Tardif 2019<br>Deftereos 2014<br>Deftereos 2013<br>Nidorf 2013<br>O'Keefe 1992<br>Total (95% CI)<br>Total events<br>Heterogeneity: Tau <sup>2</sup> :<br>Test for overall effect  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chi'<br>: Z = 0.06 (  | 2366<br>140<br>100<br>282<br>130<br><b>6382</b><br>$e^2 = 9.51$ ,<br>P = 0.96  | 44<br>5<br>10<br>2<br>124<br>df = 7 (P  | 139<br>96<br>250<br>67<br>6284<br>r = 0.22   | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%<br><b>100.0%</b><br>2);   <sup>2</sup> = 26%  | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]   | 0.1 0.2 0.5 1 2 5 1<br>Favours [Colchicine] Favours [Placebo]  |
|   | Tardif 2019<br>Deftereos 2014<br>Deftereos 2013<br>Nidorf 2013<br>O'Keefe 1992<br>Total (95% CI)<br>Total events<br>Heterogeneity: Tau <sup>2</sup> :<br>Test for overall effect  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chir<br>: Z = 0.06 (<br>Colchi  | 2366<br>140<br>100<br>282<br>130<br><b>6382</b><br>? = 9.51,<br>P = 0.96<br><b>cine</b>  | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P   | 139<br>96<br>250<br>67<br>6284<br>r = 0.22   | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%<br><b>100.0%</b><br>2);   <sup>2</sup> = 26%  | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]   | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> :         Test for overall effect         Study or Subgroup  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chir<br>: Z = 0.06 (<br>Colch<br>Mean   | 2366<br>140<br>100<br>282<br>130<br>6382<br><sup>2</sup> = 9.51,<br>P = 0.96<br>cine<br><u>5D Tota</u>   | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br><u>I Mean</u>  | 139<br>96<br>250<br>67<br>6284<br>= 0.22   | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%<br>100.0%<br>2); l <sup>2</sup> = 26%   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C   | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference<br>I IV, Random, 95% Cl   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> :         Test for overall effect         Study or Subgroup         Shah 2020  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chir<br>:: Z = 0.06 (<br>Colch<br><u>Mean</u><br>3.3 5.   | 2366<br>140<br>100<br>282<br>130<br><b>6382</b><br>? = 9.51,<br>P = 0.96<br>cine<br><u>50 Tota</u><br>93 200   | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br><u>I Mean</u><br>3 3.1   | 139<br>96<br>250<br>67<br>6284<br>= 0.22<br>acebo<br>SD<br>6.59  | 34.1%<br>7.6%<br>1.9%<br>9.3%<br>2.5%<br><b>100.0%</b><br>2); I <sup>2</sup> = 26%<br><u>Total Weig</u><br>194 22.4   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23  | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> :         Test for overall effect         Study or Subgroup         Shah 2020         Hennessy 2019  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chir<br>:: Z = 0.06 (<br>Colch<br><u>Mean</u><br>3.3 5.<br>1.6 2.   | 2366<br>140<br>100<br>282<br>130<br><b>6382</b><br>? = 9.51,<br>P = 0.96<br><u>cine</u><br><u>50 Tota</u><br>93 206<br>07 111  | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br><u>I Mean</u><br>3 3.1   | 139<br>96<br>250<br>67<br>6284<br>= 0.22<br>acebo<br>SD<br>6.59<br>3.1   | 7.6%<br>7.6%<br>9.3%<br>2.5%<br>100.0%<br>2); I <sup>2</sup> = 26%<br><u>Total Weig</u><br>194 22.4<br>111 21.0   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23<br>% -0.15 [-0.41, 0.11]   | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference<br>I IV, Random, 95% Cl   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> :         Test for overall effect         Study or Subgroup         Shah 2020         Hennessy 2019         Kajikawa 2019  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chi <sup>-</sup><br>: Z = 0.06 (<br>Colch<br><u>Mean</u> <u>\$</u><br>3.3 5.<br>1.6 2.<br>0.04 0.   | $2366 \\ 140 \\ 100 \\ 282 \\ 130 \\ 6382 \\ cine \\ cine \\ cine \\ cond \\ cond$   | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br><u>1 Mean</u><br>5 3.1<br>2<br>0.07  | 139<br>96<br>250<br>67<br>6284<br>= 0.22<br>acebo<br><u>SD</u><br>6.59<br>3.1<br>0.05  | 34.1%         7.6%         1.9%         9.3%         2.5%         100.0%         2); I² = 26%         Total Weig         194       22.4         111       21.0         14       10.2  | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23<br>% -0.15 [-0.41, 0.11<br>% -0.64 [-1.41, 0.12]   | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> :         Test for overall effect         Study or Subgroup         Shah 2020         Hennessy 2019         Kajikawa 2019         Vaidya 2017  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chi <sup>-</sup><br>: Z = 0.06 (<br>Colch<br><u>Mean</u> <u>\$</u><br>3.3 5.<br>1.6 2.<br>0.04 0.<br>1.85 (   | $2366 \\ 140 \\ 100 \\ 282 \\ 130 \\ 6382 \\ = 9.51, \\ P = 0.96 \\ \hline \\ \hline \\ cine \\ \hline \\ cine \\ \hline \\ cond \\ con$ | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br><u>1 Mean</u><br>5 3.1<br>2<br>0.07<br>2.26  | 139<br>96<br>250<br>67<br>6284<br>= 0.22<br>acebo<br><u>SD</u><br>6.59<br>3.1<br>0.05<br>1.05  | 34.1%         7.6%         1.9%         9.3%         2.5%         100.0%         2); I² = 26%         Total Weig         194 22.4         111 21.0         14 10.2         40 16.7  | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23<br>% -0.15 [-0.41, 0.11<br>% -0.64 [-1.41, 0.12<br>% -0.42 [-0.86, 0.03  | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference<br>I IV, Random, 95% Cl   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> :         Test for overall effect         Study or Subgroup         Shah 2020         Hennessy 2019         Kajikawa 2019         Vaidya 2017         Raiu 2012  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chi <sup>-</sup><br>: Z = 0.06 (<br>Colch<br>Mean <u>\$</u><br>3.3 5.<br>1.6 2.<br>0.04 0.<br>1.85 (<br>7.2 26  | $2366 \\ 140 \\ 100 \\ 282 \\ 130 \\ 6382 \\ = 9.51, \\ P = 0.96 \\ \hline \\ $  | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br><u>I Mean</u><br>5<br>3.1<br>2<br>2<br>0.07<br>) 2.26<br>2.9                       | 139<br>96<br>250<br>67<br>6284<br>2 = 0.22<br>acebo<br>5D<br>6.59<br>3.1<br>0.05<br>1.05<br>4.6  | $\begin{array}{c} 34.1\%\\ 7.6\%\\ 1.9\%\\ 9.3\%\\ 2.5\%\\ 100.0\%\\ 2); l^2 = 26\%\\ \hline 194  22.4\\ 111  21.0\\ 14  10.2\\ 40  16.7\\ 37  158 \end{array}$   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23<br>% -0.15 [-0.41, 0.11]<br>% -0.64 [-1.41, 0.12]<br>% 0.21 [-0.26, 0.03<br>% 0.21 [-0.26, 0.69]   | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> :         Test for overall effect         Study or Subgroup         Shah 2020         Hennessy 2019         Kajikawa 2019         Vaidya 2017         Raju 2012         Nidorf 2007  | 43<br>4<br>1<br>4<br>1<br>5<br>5<br>5<br>0.07; Chir<br>5<br>7<br>7<br>7<br>7<br>7<br>8<br>1.6<br>2<br>0.04<br>0<br>1.85<br>1.78<br>1.78<br>1.78   | $2366 \\ 140 \\ 100 \\ 282 \\ 130 \\ 6382 \\ cine \\ cine \\ cine \\ conditional \\ conditional$   | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br>Mean<br>5 3.1<br>2<br>0.07<br>0 2.26<br>1 2.9<br>3.7                               | 139<br>96<br>250<br>67<br>6284<br>2 = 0.22<br>acebo<br><u>SD</u><br>6.59<br>3.1<br>0.05<br>1.05<br>4.6<br>2.3  | $\begin{array}{c} 34.1\%\\ 7.6\%\\ 1.9\%\\ 9.3\%\\ 2.5\%\\ 100.0\%\\ 2); l^2 = 26\%\\ \hline \\ 194  22.4\\ 111  21.0\\ 14  10.2\\ 40  16.7\\ 37  15.8\\ 20  13.8\end{array}$   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23<br>% -0.15 [-0.41, 0.11<br>% -0.64 [-1.41, 0.12<br>% 0.21 [-0.26, 0.69<br>% -1.16 [-1.73, -0.59  | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference<br>I IV, Random, 95% Cl   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> Test for overall effect         Study or Subgroup         Shah 2020         Hennessy 2019         Kajikawa 2019         Vaidya 2017         Raju 2012         Nidorf 2007  | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chir<br>: Z = 0.06 (<br>Colch<br>Mean <u>\$</u><br>3.3 5.<br>1.6 2.<br>0.04 0.<br>1.85 (2<br>7.2 28<br>1.78 1.  | $2366 \\ 140 \\ 100 \\ 282 \\ 130 \\ 6382 \\ e = 9.51, \\ P = 0.96 \\ \hline \\ P = 0.96 \\ \hline \\ P = 0.96 \\ \hline \\ 0.9 \\ 111 \\ 0.9 \\ 40 \\ 1.9 \\ 31 \\ 23 \\ 44 \\ 646 \\ \hline \\ 0.9 \\ 40 \\ 1.9 \\ 1.9 \\ 1.0 \\ $  | 44<br>5<br>1<br>10<br>2<br>4<br>df = 7 (P<br>)<br>Pla<br>1<br>Mean<br>5<br>3.1<br>2<br>4<br>0.07<br>2.26<br>2.9<br>4<br>3.7                   | $\begin{array}{c} 2373 \\ 139 \\ 96 \\ 250 \\ 67 \\ 6284 \\ 2 = 0.22 \\ \hline \\ acebo \\ SD \\ \hline \\ ccebo \\ SD \\ \hline \\ 3.1 \\ 0.05 \\ 1.05 \\ 4.6 \\ 2.3 \\ \hline \end{array}$ | $\begin{array}{c} 34.1\% \\ 7.6\% \\ 1.9\% \\ 9.3\% \\ 2.5\% \\ 100.0\% \\ \hline \end{array}$ $\begin{array}{c} 2000000000000000000000000000000000000$   | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23<br>% -0.15 [-0.41, 0.11<br>% -0.64 [-1.41, 0.12<br>% -0.42 [-0.86, 0.03<br>% 0.21 [-0.26, 0.69<br>% -1.16 [-1.73, -0.59<br>% -0.29 [-0.64, 0.03] | 0.1 0.2 0.5 1 2 5 1<br>avours [Colchicine] Favours [Placebo]<br>Std. Mean Difference<br>I IV, Random, 95% Cl   |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> Test for overall effect         Study or Subgroup         Shah 2020         Hennessy 2019         Kajikawa 2019         Vaidya 2017         Raju 2012         Nidorf 2007         Total (95% CI)   | 43<br>4<br>1<br>4<br>135<br>= 0.07; Chi'<br>: Z = 0.06 (<br>Colch<br>Mean §<br>3.3 5.<br>1.6 2.<br>0.04 0.<br>1.85 (2<br>7.2 28<br>1.78 1.  | $2366 \\ 140 \\ 100 \\ 282 \\ 130 \\ 6382 \\ e = 9.51, \\ P = 0.96 \\ \hline \\ cine \\ 93 \\ 206 \\ cond \\ 111 \\ 23 \\ 44 \\ 446 \\ 446 \\ cond \\ 206 \\ cond \\ co$   | 44<br>5<br>1<br>10<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br>1<br>Mean<br>5<br>3.1<br>2<br>0.07<br>2.26<br>2.9<br>4<br>3.7<br>5                 | $\begin{array}{c} 2373 \\ 139 \\ 96 \\ 250 \\ 67 \\ 6284 \\ 2 = 0.22 \\ \hline \\$                           | $\begin{array}{c} 34.1\%\\ 7.6\%\\ 1.9\%\\ 9.3\%\\ 2.5\%\\ 100.0\%\\ 2); l^2 = 26\%\\ \hline \\ 104  22.4\\ 111  21.0\\ 14  10.2\\ 40  16.7\\ 37  15.8\\ 20  13.8\\ 416  100.0\\ 0); l^2 = 76\%\\ \end{array}$                                      | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23<br>% -0.15 [-0.41, 0.11<br>% -0.64 [-1.41, 0.12<br>% -0.42 [-0.86, 0.03<br>% 0.21 [-0.26, 0.69<br>% -1.16 [-1.73, -0.59<br>% -0.29 [-0.61, 0.03  | 0.1     0.2     0.5     1     2     5     10       avours [Colchicine]     Favours [Placebo]       Std. Mean Difference       IV, Random, 95% CI       I |
|   | Tardif 2019         Deftereos 2014         Deftereos 2013         Nidorf 2013         O'Keefe 1992         Total (95% CI)         Total events         Heterogeneity: Tau <sup>2</sup> Test for overall effect         Study or Subgroup         Shah 2020         Hennessy 2019         Kajikawa 2019         Vaidya 2017         Raju 2012         Nidorf 2007         Total (95% CI)         Heterogeneity: Tau <sup>2</sup> = | 43<br>4<br>1<br>4<br>1<br>35<br>= 0.07; Chi <sup>*</sup><br>:: Z = 0.06 (<br>Colch<br><u>Mean</u> <u>\$</u><br>3.3 5.<br>1.6 2.<br>0.04 0.<br>1.85 (<br>7.2 28<br>1.78 1.<br>0.11; Chi <sup>2</sup> = | $2366 \\ 140 \\ 100 \\ 282 \\ 130 \\ 6382 \\ e = 9.51, \\ P = 0.96 \\ \hline \\ cine \\ 33 \\ 206 \\ 07 \\ 111 \\ 04 \\ 14 \\ 14 \\ 14 \\ 19 \\ 40 \\ 19 \\ 31 \\ 23 \\ 44 \\ e = 20.62, \\ 0 \\ 20.62, \\ 0 \\ 20.62, \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ $   | 44<br>5<br>1<br>2<br>124<br>df = 7 (P<br>)<br>Pla<br>1 <u>Mean</u><br>5 3.1<br>2<br>5 3.1<br>2<br>0.07<br>2.26<br>2.9<br>3.7<br>1<br>1 5 (P = | 139<br>96<br>250<br>67<br>6284<br>2 = 0.22<br>acebo<br>SD<br>6.59<br>3.1<br>0.05<br>1.05<br>4.6<br>2.3   | $\begin{array}{c} 34.1\%\\ 7.6\%\\ 1.9\%\\ 9.3\%\\ 2.5\%\\ 100.0\%\\ 2); l^2 = 26\%\\ \hline \\ \hline \\ \hline \\ 104 \ 22.4\\ 111 \ 21.0\\ 14 \ 10.2\\ 40 \ 16.7\\ 37 \ 15.8\\ 20 \ 13.8\\ \hline \\ 416 \ 100.0\\ 0); l^2 = 76\%\\ \end{array}$ | 0.98 [0.65, 1.49]<br>0.79 [0.22, 2.90]<br>0.96 [0.06, 15.13]<br>0.35 [0.11, 1.12]<br>0.26 [0.02, 2.79]<br>0.99 [0.68, 1.45]<br>Std. Mean Difference<br>ht IV, Random, 95% C<br>% 0.03 [-0.16, 0.23<br>% -0.15 [-0.41, 0.11<br>% -0.64 [-1.41, 0.12<br>% -0.42 [-0.86, 0.03<br>% 0.21 [-0.26, 0.69<br>% -1.16 [-1.73, -0.59<br>% -0.29 [-0.61, 0.03  | 0.1     0.2     0.5     1     2     5     1//       avours [Colchicine]     Favours [Placebo]       Std. Mean Difference       I     IV, Random, 95% CI  |

FIGURE 3 | Meta-analysis results for myocardial infarction, stroke, all-cause death, and high-sensitive C-reactive protein (hs-CRP). (A) Myocardial infarction, (B) stroke, (C) death, (D) hs-CRP.

| Colchicine in | CAD-A | Meta-Analysis |
|---------------|-------|---------------|
|---------------|-------|---------------|

|   | NNT   | LCI    | UCI   |
|---|-------|--------|-------|
| Primary endpoint  | 36    | 26     | 58    |
| Ischemia driven<br>revascularization                    | 66    | 46     | 119   |
| Ischemia driven<br>revascularization +<br>resuscitation | 73    | 46     | 171   |
| MI  | 100   | 61     | 288   |
| Stroke  | 204   | 128    | 504   |
| Discontinuation   | 83(H) | 380(H) | 47(H) |
| H-number needed to harm                                 |       |        |       |

the sooner the treatment was introduced after a myocardial infarction (the best period up to 3 days) (27). Almost all studies showed a decrease in serum hs-CRP, but the presentation of results by individual authors varied. We managed to extract the result in the form of the mean +/- SD from six studies. In patients after treatment with colchicine (n = 446), the mean value of hs-CRP was 1.78 mg% compared with 3.7 mg% in the placebo group (n = 416) (Figure 3D). In patients with ACS, elevated levels of hs - CRP, interleukin-1, and interleukin-6 are indicators of the risk of cardiovascular complications (28-31). Treatment with colchicine in comparison with placebo leads to a greater reduction in the volume of atherosclerotic plaque, and changes in its volume also correlate with changes in serum hs-CRP levels (8). Therefore, in patients with CAD, the combination of colchicine with aggressive statin therapy seems to be justified and desired (28, 30).

Generally, colchicine is well tolerated. However, in many studies, several side effects were observed. Compared with placebo, the occurrence of diarrhea (17.9 vs. 13.1%) and gastrointestinal disorders (17.6 vs 13.1%) was significantly more frequent. There were no significant increase in hepatic, muscle, infectious, hematological complications, sensory disturbances, serious side effects, and deaths (2, 32). The dose of colchicine used in cardiovascular diseases is 0.5 mg once daily and is lower than in the treatment of rheumatoid diseases.

In patients with cardiovascular diseases, simple gastrointestinal side effects are most common, leading them however to discontinue treatment. We found data on patients who discontinued the drug because of side effects in 10 studies. Colchicine was discontinued by 10.2% (648/6,350) of the patients and by 8.7% (549/6,264) of the placebo/control group. Compared with placebo, the relative risk of colchicine withdrawal was 60% (RR 1.60 95% CI 1.06-2.42) (Figure 5A). After excluding the non-placebo trials (21, 26, 33), the risk of withdrawal was reduced by half (RR 1.34 95% CI.97-1.84) (Figure 5B). We calculated the Net Clinical endpoint (colchicine vs. placebo) as the difference between the reduction of the composite endpoint (benefit) and the increase in the number of patients discontinuing treatment due to side effects (harm). However, in individual studies, the follow-up time varied significantly from 1 to 28 months, not all studies used a placebo (PROBE study) (17, 21, 33), and the sample size ranged from 44 to 5,522 patients. In the three largest studies with a composite endpoint, a placebo was used, the follow-up was over 6 months, and the number of subjects was over 100 in each arm (10–12), while the risk of discontinuation of colchicine treatment was reduced to 26% (**Figure 5C**).

Taking into account the risk of discontinuation of colchicine treatment, the estimated potential benefit from the continued use of the drug covers 18/1,000 patients and this ratio is statistically significant (p = 0.001, Figure 5D). From a clinical point of view, the values of NNT 36 (26-58) for the primary endpoint and NNH 83 (380-47) for the occurrence of side effects causing discontinuation are interesting and acceptable. In all studies, these favorable results were seen in patients treated with statins and antiplatelet drugs. Colchicine is a cheap drug, and if added to the standard treatment of patients with ischemic heart disease, it can significantly enhance the power of preventive therapy at a low cost. Although colchicine does not reduce the risk of cardiovascular mortality in patients with ACS and CCS, colchicine should be considered to reduce cardiovascular morbidity in patients who tolerate the drug.

## **Study Limitations**

Some limitations of this analysis should be addressed. First, the results of original studies are limited by the heterogeneity across the trials and the possibility of publication bias (acute vs. chronic coronary syndromes, gender, various age groups, various number of endpoints in the studies). However, we tried to minimize the influence of these limitations, including the application of the random-effects model and sensitivity analysis, incorporating to the analysis only the studies with both arms where the number of patients was above 100. Secondly, the definition of primary endpoints across the trials differed. That is why all components of the primary endpoint were analyzed separately. Such definition of primary endpoints also influenced the robustness of net clinical benefit. Finally, the hs-CRP results were presented in different descriptive statistics, and its analysis required some transformations.

# CONCLUSION

In CAD, low-dose colchicine (0.5 mg once daily) significantly reduces the risk of the primary composite endpoint by about 30%. The drug should be considered part of the preventive as treatment in patients with good tolerance. When added to standard therapy, it significantly reduces cardiovascular morbidity.



FIGURE 5 | Meta-analysis for the therapy discontinuation and net clinical benefit for all analyzed studies and sensitivity analysis. (A) Colchicine therapy discontinuation-all studies, (B) colchicine therapy discontinuation without PROBE studies, (C) colchicine therapy discontinuation sensitivity analysis, (D) net clinical benefit sensitivity analysis.

# DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

# **AUTHOR CONTRIBUTIONS**

SG: conceptualization, methodology, analysis, original draft preparation, and supervision. MM: software, methodology, and

## REFERENCES

- Stack R, Ryan J, McCarthy G. Colchicine: new insights to an old drug. Am J Therapeutics. (2015) 22:e151–157. doi: 10.1097/01.mjt.0000433937.07244.e1
- Hemkens LG, Ewald H, Gloy V, Arpagaus A, Olu K, Nidorf M, et al. Cardiovascular effects and safety of long-term colchicine treatment: cochrane review and meta-analysis. *Heart.* (2016) 102:590–6. doi: 10.1136/heartjnl-2015-308542
- Fiolet ATL, Opstal TSJ, Mosterd A, Eikelboom JW, Jolly SS, Keech AC et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. *Eur Heart J.* (2021) 42:2765–75. doi: 10.1093/eurheartj/ehab115
- Fujisue K, Sugamura K, Kurokawa H, Matsubara J, Ishii M, Izumiya Y, et al. Colchicine improves survival, left ventricular remodeling, and chronic cardiac function after acute myocardial infarction. *Circ J.* (2017) 81:1174– 82 doi: 10.1253/circj.CJ-16-0949
- Roubille F, Tardif JC. Colchicine for secondary cardiovascular prevention in coronary disease. *Circulation*. (2020) 142:1901– 4. doi: 10.1161/CIRCULATIONAHA.120.051240
- Opstal SJ, Hoogeveen R, Fiolet AT, Silvis M, The SHK, Bax WA, et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artesry disease: a LoDoCo2 proteomic substudy. *Circulation*. (2020) 142:1996–8. doi: 10.1161/CIRCULATIONAHA.120.050560
- Kajikawa M, Higashi Y, Tomiyama H, Maruhashi T, Kurisu S, Kihara Y, et al. Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. *Int J Cardiol.* (2019) 281:35– 9. doi: 10.1016/j.ijcard.2019.01.054
- Vaidya K, Arnott C, Martinez G, Ng B, McCormack S, Sullivan D, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study. J Am Coll Cardiol. (2018) 11:305–16. doi: 10.1016/j.jcmg.2017.08.013
- Tucker B, Vaidya K, Kurup R, Khandkar C, Barraclough J, Misra A, et al. Colchicine inhibits neutrophil extracellular trap formation in acute coronary syndrome patients post percutaneous coronary intervention. J Am Coll Cardiol. (2020) 75 (11suppl1):1346. doi: 10.1016/S0735-1097(20)31973-2
- Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggoni AP et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Eng J Med. (2019) 381:2497–505. doi: 10.1056/NEJMoa1912388
- Nidorf SM, Fiolet AT, Mosterd JW, Eikelboom A, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary diseae. *N Eng J Med.* (2020) 383:1838–47. doi: 10.1056/NEJMoa2021372
- Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H, et al. Colchicine in patients wit acute coronary syndrome: the Australian COPS randomized clinical trial. *Circulation*. (2020) 142:1890– 900. doi: 10.1161/CIRCULATIONAHA.120.050771
- Al-Abdouh A, Barbarawi M, Khan SU, Osman M, Upadhrasta S, Solipuram V, et al. Colchicine therapy in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. *Coron Artery Dis.* (2021) 32:441–47. doi: 10.1097/MCA.00000000000931
- Ullah W, Gowda SN, Fischman D. Safety and efficacy of colchicine in patients with coronary artery disease: a systematic review and metaanalysis. *Cardiovasc Revasc Med.* (2021) 23:1–6. doi: 10.1016/j.carrev.2020. 06.004

draft editing. TU: analysis and draft editing. AO-W: analysis, methodology, and draft editing. All authors contributed to the article and approved the submitted version.

#### SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm. 2021.740896/full#supplementary-material

- Aimo A, Pascual Figal DA, Bayes-Genis A, Emdin M, Georgiopoulos G. Effect of low-dose colchicine in acute and chronic syndromes: a systematic review and meta-analysis. *Eur J Clin Invest.* (2020) 51:e13464. doi: 10.1111/eci.13464
- Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD. Effects of acute colchicine administration prior to percutaneous coronary intervention: Colchicine-PCI Randomized Trial. *Circ Cardiovasc Interv.* (2020) 13:e008717. doi: 10.1161/CIRCINTERVENTIONS.119.008717
- Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. (2013) 61:404–10. doi: 10.1016/j.jacc.2012.10.027
- Deftereos S, Giannopoulos G, Panagopoulou V, Bouras G, Raisakis K et al. Anti-inflamatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. J Am Coll Cardiol Heart Fail. (2014) 2:131– 7. doi: 10.1016/j.jchf.2013.11.006
- Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol. (2013) 61:167 9– 85. doi: 10.1016/j.jacc.2013.01.055
- Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S, et al. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. *Am Heart J.* (2019) 215:62–9. doi: 10.1016/j.ahj.2019. 06.003
- Akodad M, Lattuca B, Nagot N, Georgescu V, Buisson M, Cristol JP, et al. COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. *Arch Cardiovasc Dis.* (2017) 110:395–402. doi: 10.1016/j.acvd.2016.10.004
- Raju Nc, Yi Q, Nidorf M, Fagel ND, Hiralal R, Eikelboom JW. Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. *J Thromb.* (2012) 33:88–94. doi: 10.1007/s11239-01 1-0637-y
- O'Keefe Jr JH, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. (1992) 7:1597–600. doi: 10.1016/0735-1097(92)90624-V
- Nidorf M, Thompson PL. Effect of colchicine (0. 5mg twice daily) on highsensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. *Am J Cardiol.* (2007) 99:805– 7. doi: 10.1016/j.amjcard.2006.10.039
- Xia M, Yang X. Qian Ch. Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease. *Am J Cardiol.* (2021) 140:33–8. doi: 10.1016/j.amjcard.2020.10.043
- Samuel M, Tardif JC, Bouabdallaoui N, Khairy P, Dube MP, Blondeau L, Guertin MC. Colchicine for secondary of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. *Can J Cardiol.* (2021). 37:776–85. doi: 10.1016/j.cjca.2020. 10.006
- 27. Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT). *Eur Heart J.* (2020) 41:4092–9. doi: 10.1093/eurheartj/ehaa659

- Ridker PM. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipidlowering and inflammation-inhibiting agents? *Cirtculation.* (2020) 141:787– 9. doi: 10.1161/CIRCULATIONAHA.119.045256
- 29. Silvain J, Kerneis M, Zeitouni M, Lattuca B, Galier S, Brugier D et al. Interleukin-1β and risk of premature death in patients with myocardial infarction. J Am Coll Cardiol. (2020) 76:1763– 73. doi: 10.1016/j.jacc.2020.08.026
- Ridker PM. Targeting interleukin-1 and interleukin-6: the time has come to aggressivelly address residual inflammatory risk. J Am Coll Cardiol. (2020) 76:1774–6. doi: 10.1016/j.jacc.2020. 08.052
- Cho KI Yu J, Hayashi T, Han SH, Koh KK. Strategies to overcome residual risk during statins era. *Circ J.* (2019) 83:1973–9. doi: 10.1253/circj.CJ-19-0624
- 32. Stewart S, Yang KCK, Atkins K, Dalbeth N, Robinson PC. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomized trials. Arthritis Res Therapy. (2020) 22:28. doi: 10.1186/s13075-020-2120-7
- 33. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design forintervention trials

prospective randomized open blinded end-point. *Blood Pressure.* (1992) 1:113-9. doi: 10.3109/08037059209077502

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Grajek, Michalak, Urbanowicz and Olasińska-Wiśniewska. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.